Lycia Therapeutics, Inc S-1, filed Oct 5, 2026

Lycia Therapeutics, Inc. (LYCA)

Lycia Therapeutics, Inc. is pursuing an initial public offering and Nasdaq Global Market listing under “LYCA.” Phase 1 data for LCA-0061 showed a mean maximum IgE reduction of 96% after a single 70 mg dose, while LCA-0321 is in Phase 1 for Graves’ disease. AI summary